CHALLENGES FOR ASSESSING THE ECONOMIC VALUE OF ORPHAN DRUGS - A LITERATURE REVIEW OF CURRENT AND ALTERNATIVE APPROACHES

被引：4
|
作者：
Cote, S. [1 ]
Gaudig, M.
Nielsen, S. K. [2 ,3 ]
Shields, G. E. [4 ]
Britton, J. A. [4 ]
机构：
[1] Janssen Cilag, High Wycombe, Bucks, England
[2] Janssen Hlth Econ & Market Access EMEA, Neuss, Germany
[3] BresMed, Panaji, India
[4] BresMed, Sheffield, S Yorkshire, England
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.2026
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY126
引用
收藏
页码：A681 / A681
页数：1
相关论文
共 50 条
  • [21] Current approaches and challenges for patient engagement in real-world studies: a targeted literature review
    Hanekamp, Eline
    Van Delden, Liselotte
    O'Callaghan, Amy
    Ewins, Eleanor
    Bell, Juliet
    Edwards, Victoria
    Van den Broek, Remon
    Huang, Yunyu
    CURRENT MEDICAL RESEARCH AND OPINION, 2023, 39 : S15 - S16
  • [22] The quality of economic evaluations of ultra-orphan drugs in Europe - a systematic review
    Schuller, Y.
    Hollak, C. E. M.
    Biegstraaten, M.
    ORPHANET JOURNAL OF RARE DISEASES, 2015, 10
  • [23] The quality of economic evaluations of ultra-orphan drugs in Europe – a systematic review
    Y. Schuller
    C. E. M. Hollak
    M. Biegstraaten
    Orphanet Journal of Rare Diseases, 10
  • [24] Assessing the Economic Value of Clinical Artificial Intelligence: Challenges and Opportunities
    Hendrix, Nathaniel
    Veenstra, David L.
    Cheng, Mindy
    Anderson, Nicholas C.
    Verguet, Stephane
    VALUE IN HEALTH, 2022, 25 (03) : 331 - 339
  • [25] 'Beyond GDP' in cities: Assessing alternative approaches to urban economic development
    Crisp, Richard
    Waite, David
    Green, Anne
    Hughes, Ceri
    Lupton, Ruth
    MacKinnon, Danny
    Pike, Andy
    URBAN STUDIES, 2024, 61 (07) : 1209 - 1229
  • [26] AN ECONOMIC-ANALYSIS OF ALTERNATIVE APPROACHES TO THE PROBLEM OF CONTROLLING HARD DRUGS
    POMMEREHNE, WW
    HARTMANN, HC
    JAHRBUCH FUR SOZIALWISSENSCHAFT, 1980, 31 (01): : 102 - 143
  • [27] Assessing the value of orphan drugs using conventional cost-effectiveness analysis: Is it fit for purpose?
    Postma, Maarten J.
    Noone, Declan
    Rozenbaum, Mark H.
    Carter, John A.
    Botteman, Marc F.
    Fenwick, Elisabeth
    Garrison, Louis P.
    ORPHANET JOURNAL OF RARE DISEASES, 2022, 17 (01)
  • [28] Assessing the value of orphan drugs using conventional cost-effectiveness analysis: Is it fit for purpose?
    Maarten J. Postma
    Declan Noone
    Mark H. Rozenbaum
    John A. Carter
    Marc F. Botteman
    Elisabeth Fenwick
    Louis P. Garrison
    Orphanet Journal of Rare Diseases, 17
  • [29] ASSESSING THE RELATIONSHIP BETWEEN LIFELONG VALUE AND PRICING FOR ORPHAN DRUGS IN ULTRA-RARE DISEASES
    Dabbous, O.
    Zhou, Z. Y.
    Tang, C.
    Harvey, M.
    Wu, E. Q.
    Arjunji, R.
    VALUE IN HEALTH, 2019, 22 : S388 - S388
  • [30] Challenges in Measuring the Societal Value of Orphan Drugs: Insights from a Canadian Stated Preference Survey
    Dragojlovic, Nick
    Rizzardo, Shirin
    Bansback, Nick
    Mitton, Craig
    Marra, Carlo A.
    Lynd, Larry D.
    PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2015, 8 (01): : 93 - 101
12345